» Articles » PMID: 17071637

Recognition of Nucleotide Analogs Containing the 7,8-dihydro-8-oxo Structure by the Human MTH1 Protein

Overview
Journal J Biochem
Specialty Biochemistry
Date 2006 Oct 31
PMID 17071637
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The MTH1 protein catalyzes hydrolysis of oxidatively damaged purine nucleotides including 8-hydroxy-dGTP to the monophosphates. The MTH1 protein seems to act as an important defense system against mutagenesis, carcinogenesis, and cell death induced by oxidized purine nucleotides. We previously reported that the functional groups at the 2- and 6-positions of the purine ring affect the recognition by the human MTH1 protein. 8-Hydroxy-dGTP and 8-hydroxy-dATP are substrates of MTH1, and both have the "7,8-dihydro-8-oxo structure." In this study, three nucleotide analogs containing this motif were examined. A synthetic purine analog containing the 7,8-dihydro-8-oxo structure and the 2-amino function (dJTP) was hydrolyzed to the monophosphate with high efficiency by MTH1. On the other hand, two analogs that lack the two-ring system of their bases [formamidopyrimidine-dGTP (FAPY-dGTP) and 2-OH-dYTP] were poor substrates. FAPY-dGTP is a mixture of conformers and was hydrolyzed more than ten-fold less efficiently than 8-hydroxy-dGTP. These results clarify the effects of the 2-amino group and the two-ring system of the purine base on the recognition by the human MTH1 protein.

Citing Articles

Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer.

Chen D, Zhang R, Xie A, Yuan J, Zhang J, Huang Y Bioengineered. 2021; 12(2):9779-9789.

PMID: 34696672 PMC: 8809933. DOI: 10.1080/21655979.2021.1995104.


A guardian residue hinders insertion of a Fapy•dGTP analog by modulating the open-closed DNA polymerase transition.

Smith M, Shock D, Beard W, Greenberg M, Freudenthal B, Wilson S Nucleic Acids Res. 2019; 47(6):3197-3207.

PMID: 30649431 PMC: 6451102. DOI: 10.1093/nar/gkz002.


NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma.

Wang Y, Wan F, Chang K, Lu X, Dai B, Ye D Oncol Lett. 2017; 14(5):6121-6128.

PMID: 29113256 PMC: 5661574. DOI: 10.3892/ol.2017.6997.


Understanding the molecular mechanism for the differential inhibitory activities of compounds against MTH1.

Wang M, Zhou S, Chen Q, Wang L, Liang Z, Wang J Sci Rep. 2017; 7:40557.

PMID: 28074893 PMC: 5225434. DOI: 10.1038/srep40557.


MTH1 Substrate Recognition--An Example of Specific Promiscuity.

Nissink J, Bista M, Breed J, Carter N, Embrey K, Read J PLoS One. 2016; 11(3):e0151154.

PMID: 26999531 PMC: 4801406. DOI: 10.1371/journal.pone.0151154.